Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This study will explore the effectiveness and safety of the combination therapy of anlotinib , penpulimab and SBRT in patients with metastatic non-small Cell Lung Cancer (NSCLC)
Epistemonikos ID: 96f60082cd5b81e56ef1afc55594ec5a150ba7cc
First added on: May 13, 2024